VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q40470156 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233021.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q40470156‏
024 ‎‡a 0000-0001-7934-9130‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q40470156‏
100 0 ‎‡a Xavier Calvo‏ ‎‡9 ast‏ ‎‡9 es‏ ‎‡9 sl‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Xavier Calvo‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Xavier Calvo‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's artikull shkencor i botuar në vitin 2022‏
670 ‎‡a Author's Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia‏
670 ‎‡a Author's Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms‏
670 ‎‡a Author's Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group‏
670 ‎‡a Author's Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas‏
670 ‎‡a Author's Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of p‏
670 ‎‡a Author's Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.‏
670 ‎‡a Author's Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.‏
670 ‎‡a Author's Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del‏
670 ‎‡a Author's Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.‏
670 ‎‡a Author's Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).‏
670 ‎‡a Author's Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes‏
670 ‎‡a Author's Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression‏
670 ‎‡a Author's Excess mortality in the myelodysplastic syndromes.‏
670 ‎‡a Author's Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia‏
670 ‎‡a Author's Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ( "accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior‏
670 ‎‡a Author's (In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes.‏
670 ‎‡a Author's Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?‏
670 ‎‡a Author's LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.‏
670 ‎‡a Author's Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.‏
670 ‎‡a Author's Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA‏
670 ‎‡a Author's Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features‏
670 ‎‡a Author's Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma‏
670 ‎‡a Author's Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.‏
670 ‎‡a Author's Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.‏
670 ‎‡a Author's Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.‏
670 ‎‡a Author's Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.‏
670 ‎‡a Author's Reply to M.A. Lichtman‏
670 ‎‡a Author's Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL‏
670 ‎‡a Author's Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia‏
670 ‎‡a Author's Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT.‏
670 ‎‡a Author's The importance of adequate recognition of normal and dysplastic myelopoiesis for the diagnosis of myelodysplastic syndromes‏
670 ‎‡a Author's Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS‏
670 ‎‡a Author's Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma‏
909 ‎‡a (orcid) 0000000179349130‏ ‎‡9 1‏
912 ‎‡a artikullshkencor1botuarnevitin‏ ‎‡A artikull shkencor i botuar në vitin 2022‏ ‎‡9 1‏
919 ‎‡a chroniclymphocyticleukemialikemonoclonalbcelllymphocytosisexhibitsanincreasedinflammatorysignaturethatisreducedinearlystagechroniclymphocyticleukemia‏ ‎‡A Chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis exhibits an increased inflammatory signature that is reduced in early-stage chronic lymphocytic leukemia‏ ‎‡9 1‏
919 ‎‡a treatmentwithgcsfreducesacutemyeloidleukemiablastviabilityinthepresenceofbonemarrowstroma‏ ‎‡A Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma‏ ‎‡9 1‏
919 ‎‡a therapyrelatedmyelodysplasticsyndromesdeservespecificdiagnosticsubclassificationandriskstratificationanapproachtoclassificationofpatientswithtmds‏ ‎‡A Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS‏ ‎‡9 1‏
919 ‎‡a importanceofadequaterecognitionofnormalanddysplasticmyelopoiesisforthediagnosisofmyelodysplasticsyndromes‏ ‎‡A The importance of adequate recognition of normal and dysplastic myelopoiesis for the diagnosis of myelodysplastic syndromes‏ ‎‡9 1‏
919 ‎‡a serialintestinalendoscopicexaminationsofpatientswithpersistentdiarrheaafterallosct‏ ‎‡A Serial intestinal endoscopic examinations of patients with persistent diarrhea after allo-SCT.‏ ‎‡9 1‏
919 ‎‡a rituximabmaintenanceafter1linetherapywithrituximabfludarabinecyclophosphamideandmitoxantronerfcmforchroniclymphocyticleukemia‏ ‎‡A Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia‏ ‎‡9 1‏
919 ‎‡a restrictedtcellreceptorrepertoireinclllikemonoclonalbcelllymphocytosisandearlystagecll‏ ‎‡A Restricted T cell receptor repertoire in CLL-like monoclonal B cell lymphocytosis and early stage CLL‏ ‎‡9 1‏
919 ‎‡a replyto1000alichtman‏ ‎‡A Reply to M.A. Lichtman‏ ‎‡9 1‏
919 ‎‡a refiningthebreakpointsof3newtranslocationsidentifiedinmyelodysplasticsyndromes‏ ‎‡A Refining the Breakpoints of Three New Translocations Identified in Myelodysplastic Syndromes.‏ ‎‡9 1‏
919 ‎‡a reciprocaltranslocationsinmyelodysplasticsyndromesandchronicmyelomonocyticleukemiasreviewof5654patientswithanevaluablekaryotype‏ ‎‡A Reciprocal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemias: review of 5,654 patients with an evaluable karyotype.‏ ‎‡9 1‏
919 ‎‡a prognosticimpactofcirculatingplasmacellsinpatientswithmultiplemyelomaimplicationsforplasmacellleukemiadefinition‏ ‎‡A Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition.‏ ‎‡9 1‏
919 ‎‡a prognosticimpactofchromosomaltranslocationsinmyelodysplasticsyndromesandchronicmyelomonocyticleukemiapatientsastudybythespanishgroupofmyelodysplasticsyndromes‏ ‎‡A Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes.‏ ‎‡9 1‏
919 ‎‡a pharmacologicalmodulationofcxcr4cooperateswithbetbromodomaininhibitionindiffuselargebcelllymphoma‏ ‎‡A Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma‏ ‎‡9 1‏
919 ‎‡a oligomonocyticandovertchronicmyelomonocyticleukemiashowsimilarclinicalgenomicandimmunophenotypicfeatures‏ ‎‡A Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features‏ ‎‡9 1‏
919 ‎‡a molecularandcytogeneticcharacterizationofmyelodysplasticsyndromesincellfreedna‏ ‎‡A Molecular and cytogenetic characterization of myelodysplastic syndromes in cell-free DNA‏ ‎‡9 1‏
919 ‎‡a lossoftheimmunecheckpointcd85jlilrb1onmalignantplasmacellscontributestoimmuneescapeinmultiplemyeloma‏ ‎‡A Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.‏ ‎‡9 1‏
919 ‎‡a lmo2negativeexpressionpredictsthepresenceofmyctranslocationsinaggressivebcelllymphomas‏ ‎‡A LMO2-negative Expression Predicts the Presence of MYC Translocations in Aggressive B-Cell Lymphomas.‏ ‎‡9 1‏
919 ‎‡a isthereapressingneedforimprovingprognosticationstrategiesintherapyrelatedmyelodysplasticsyndromes‏ ‎‡A Is there a pressing need for improving prognostication strategies in therapy-related myelodysplastic syndromes?‏ ‎‡9 1‏
919 ‎‡a inconvenienceofaddingageandcomorbiditiestoprognosticmodelsinmyelodysplasticsyndromes‏ ‎‡A (In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes.‏ ‎‡9 1‏
919 ‎‡a expandedandhighlyactiveproliferationcentersidentifyahistologicalsubtypeofchroniclymphocyticleukemiaacceleratedchroniclymphocyticleukemiawithaggressiveclinicalbehavior‏ ‎‡A Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ( "accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior‏ ‎‡9 1‏
919 ‎‡a expandedandhighlyactiveproliferationcentersidentifyahistologicalsubtypeofchroniclymphocyticleukemia‏ ‎‡A Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia‏ ‎‡9 1‏
919 ‎‡a excessmortalityinthemyelodysplasticsyndromes‏ ‎‡A Excess mortality in the myelodysplastic syndromes.‏ ‎‡9 1‏
919 ‎‡a evolving1000proteinpatterninpatientswithsmolderingmultiplemyelomaimpactonearlyprogression‏ ‎‡A Evolving M-protein pattern in patients with smoldering multiple myeloma: impact on early progression‏ ‎‡9 1‏
919 ‎‡a erythroleukemiasharesbiologicalfeaturesandoutcomewithmyelodysplasticsyndromeswithexcessblastsarationaleforitsinclusionintofutureclassificationsofmyelodysplasticsyndromes‏ ‎‡A Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes‏ ‎‡9 1‏
919 ‎‡a enumeratingbonemarrowblastsfromnonerythroidcellularityimprovesoutcomepredictioninmyelodysplasticsyndromesandpermitsabetterdefinitionoftheintermediateriskcategoryoftherevisedinternationalprognosticscoringsystemipssr‏ ‎‡A Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).‏ ‎‡9 1‏
919 ‎‡a efficacyoflenalidomideinapatientwithmyelodysplasticsyndromewithisolateddel5qandjak2v617fmutation‏ ‎‡A Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.‏ ‎‡9 1‏
919 ‎‡a efficacyoflenalidomideinapatientwithmyelodysplasticsyndromewithisolateddel‏ ‎‡A Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del‏ ‎‡9 1‏
919 ‎‡a efficacyandtolerabilityofhydroxyureainthetreatmentofthehyperproliferativemanifestationsofmyelofibrosisresultsin40patients‏ ‎‡A Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients.‏ ‎‡9 1‏
919 ‎‡a consideringbonemarrowblastsfromnonerythroidcellularityimprovestheprognosticevaluationofmyelodysplasticsyndromes‏ ‎‡A Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.‏ ‎‡9 1‏
919 ‎‡a comparisonof3prognosticscoringsystemsinaseriesof146casesofchronicmyelomonocyticleukemiacmml1500andersonprognosticscoremdapscmmlspecificprognosticscoringsystemcpssandmayoprognosticmodeladetailedreviewofp‏ ‎‡A Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of p‏ ‎‡9 1‏
919 ‎‡a clinicalinterestoflmo2testingforthediagnosisofaggressivelargebcelllymphomas‏ ‎‡A Clinical Interest of LMO2 Testing for the Diagnosis of Aggressive Large B-Cell Lymphomas‏ ‎‡9 1‏
919 ‎‡a clinicalandbiologicalsignificanceofisolatedychromosomelossinmyelodysplasticsyndromesandchronicmyelomonocyticleukemiaareportfromthespanishmdsgroup‏ ‎‡A Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group‏ ‎‡9 1‏
919 ‎‡a circulatingcellfreednaimprovesthemolecularcharacterisationofphnegativemyeloproliferativeneoplasms‏ ‎‡A Circulating cell-free DNA improves the molecular characterisation of Ph-negative myeloproliferative neoplasms‏ ‎‡9 1‏
943 ‎‡a 202x‏ ‎‡A 2022‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 DNB|1277307024‏
996 ‎‡2 SUDOC|23544930X‏
996 ‎‡2 ISNI|0000000394692791‏
996 ‎‡2 NKC|jo2014825109‏
996 ‎‡2 SIMACOB|341179491‏
996 ‎‡2 BNC|981058512954006706‏
996 ‎‡2 ISNI|0000000059754369‏
996 ‎‡2 NYNYRILM|171378‏
996 ‎‡2 BNE|XX951114‏
996 ‎‡2 BIBSYS|3098120‏
996 ‎‡2 BNCHL|10000000000000000280946‏
996 ‎‡2 BNC|981061094321806706‏
996 ‎‡2 BNC|981058526488206706‏
996 ‎‡2 J9U|987011854984805171‏
996 ‎‡2 PLWABN|9812072664905606‏
996 ‎‡2 NTA|072086556‏
996 ‎‡2 BNE|XX985710‏
996 ‎‡2 CAOONL|ncf11956884‏
996 ‎‡2 ISNI|0000000116314811‏
996 ‎‡2 BNC|981060034304806706‏
996 ‎‡2 LC|n 2001035101‏
996 ‎‡2 BNE|XX5528900‏
996 ‎‡2 LC|n 00103294‏
996 ‎‡2 BNC|981058554943206706‏
996 ‎‡2 NTA|238331121‏
996 ‎‡2 SUDOC|201752549‏
996 ‎‡2 BNF|18039062‏
996 ‎‡2 BNE|XX855409‏
996 ‎‡2 ISNI|0000000066372481‏
996 ‎‡2 BNE|XX1002207‏
996 ‎‡2 ISNI|0000000059333687‏
996 ‎‡2 DNB|13274113X‏
996 ‎‡2 ISNI|0000000110597355‏
996 ‎‡2 BNC|981058510005906706‏
996 ‎‡2 BNE|XX4868677‏
996 ‎‡2 NII|DA08840526‏
996 ‎‡2 BNE|XX1473927‏
996 ‎‡2 DNB|108913908X‏
996 ‎‡2 BNE|XX895443‏
996 ‎‡2 BNE|XX1112209‏
996 ‎‡2 SUDOC|273576895‏
996 ‎‡2 J9U|987007438169205171‏
996 ‎‡2 NKC|osd20211105773‏
996 ‎‡2 ISNI|0000000436525511‏
996 ‎‡2 BNC|981058513132606706‏
996 ‎‡2 BNE|XX4586728‏
996 ‎‡2 SUDOC|100536387‏
996 ‎‡2 BNCHL|10000000000000000150752‏
996 ‎‡2 BNCHL|10000000000000000150753‏
996 ‎‡2 LC|no2019018815‏
996 ‎‡2 BNE|XX871579‏
996 ‎‡2 NUKAT|n 2008072104‏
996 ‎‡2 BNE|XX1543827‏
996 ‎‡2 BNC|981058518847806706‏
996 ‎‡2 BNF|16256482‏
996 ‎‡2 RERO|A000027678‏
996 ‎‡2 DNB|174303106‏
996 ‎‡2 BNE|XX1782318‏
996 ‎‡2 LC|n 2014060058‏
996 ‎‡2 CAOONL|ncf11464077‏
996 ‎‡2 LC|n 2021055311‏
996 ‎‡2 NTA|288363051‏
996 ‎‡2 DNB|139656634‏
996 ‎‡2 BNF|16953985‏
996 ‎‡2 DNB|1057562033‏
996 ‎‡2 NSK|000464848‏
996 ‎‡2 SUDOC|23304342X‏
996 ‎‡2 ISNI|0000000043678015‏
996 ‎‡2 RERO|A000081998‏
996 ‎‡2 BNE|XX6470869‏
996 ‎‡2 BAV|495_355573‏
996 ‎‡2 DNB|1316984117‏
996 ‎‡2 BNE|XX4952879‏
996 ‎‡2 BNE|XX954647‏
996 ‎‡2 ISNI|0000000059510399‏
996 ‎‡2 BNE|XX1112496‏
996 ‎‡2 NUKAT|n 02061532‏
996 ‎‡2 DNB|1141832305‏
996 ‎‡2 BNC|981058519549706706‏
996 ‎‡2 BNC|981058522905806706‏
996 ‎‡2 PTBNP|1910888‏
996 ‎‡2 LC|n 88039396‏
996 ‎‡2 BNE|XX4823952‏
996 ‎‡2 ISNI|000000005919877X‏
996 ‎‡2 BNCHL|10000000000000000120897‏
996 ‎‡2 SUDOC|179516116‏
996 ‎‡2 LC|n 86138145‏
996 ‎‡2 ISNI|0000000115896717‏
996 ‎‡2 BNC|981058526842606706‏
996 ‎‡2 BNF|12056240‏
996 ‎‡2 BNE|XX873253‏
996 ‎‡2 DNB|1176466291‏
996 ‎‡2 SUDOC|06717194X‏
996 ‎‡2 BNE|XX1333047‏
996 ‎‡2 DNB|1293995592‏
996 ‎‡2 BNE|XX1137410‏
996 ‎‡2 SUDOC|028801342‏
996 ‎‡2 LC|nb2008027497‏
996 ‎‡2 BNE|XX1460736‏
996 ‎‡2 BIBSYS|90211465‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏